Hepatitis B is potentially a life-threatening liver infection caused by the Hepatitis B Virus (HBV). It is a major global health problem and it can be an acute infection or a chronic infection. Chronic HBV infection is a leading cause of chronic hepatitis and advanced-stage liver diseases, including cirrhosis and hepatocellular carcinoma (HCC).
Hepatitis B virus (HBV) is a blood-borne and sexually transmitted virus that is acquired by percutaneous and mucosal exposure to blood or other body fluids of an infected person. Clinical manifestations of hepatitis from different origins may be quite similar.
Most people do not experience any symptom during the acute infection phase. However, some people have acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain.
The Hepatitis B Virus market report covers emerging drugs, current treatment practices, Hepatitis B Virus market share of the individual therapies, current and forecasted Hepatitis B Virus Market Size from 2017 to 2030 segmented by seven major markets.
The report also provides detailed current Hepatitis B Virus treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Hepatitis B Virus Market Key Facts
In the Global Burden of Disease Study, 2010, HBV Infection is estimated to have 786,000 deaths and the vast majority being attributable to liver cancer (341,000 deaths) and cirrhosis (312,000 deaths), as per Lozano et al., 2012.
According to the World Health Organization, about 2 billion people worldwide have been infected with the Hepatitis B Virus and about 360 million live with chronic Hepatitis B infection.
As per European Centre for Disease Prevention and Control (ECDC), the prevalence of HBV in the general population is heterogeneous in Europe ranging 0.1-7 % depending on the country.
The global prevalence of HBV infection varies widely.
Visit For Sample Pages:
Key Benefits of Hepatitis B Virus Market Report
Hepatitis B Virus market report provides an in-depth analysis of Hepatitis B Virus Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Hepatitis B Virus market report will help in developing business strategies by understanding the Hepatitis B Virus Market trends & developments, key players and future market competition that will shape and drive the Hepatitis B Virus market in the upcoming years.
The Hepatitis B Virus market report covers Hepatitis B Virus current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Hepatitis B Virus market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Hepatitis B Virus market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hepatitis B Virus market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Hepatitis B Virus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Hepatitis B Virus Epidemiology
The Hepatitis B Virus epidemiology section covers insights about historical and current Hepatitis B Virus patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The Hepatitis B Virus Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis B Virus market or expected to get launched in the market during the study period. The analysis covers Hepatitis B Virus market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key players, such as Ascentage Pharma, Replicor, Ionis Pharma, Gilead Sciences, Arbutus Biopharma, Spring Bank Pharmaceuticals, MYR Pharma, GC Pharma, and Altimmune, etc. are involved in developing therapies for Hepatitis B virus infection.
Table of Contents
1. Key Insights
2. Executive Summary
3. Hepatitis B Virus Competitive Intelligence Analysis
4. Hepatitis B Virus Market Overview at a Glance
5. Hepatitis B Virus Disease Background and Overview
6. Hepatitis B Virus Patient Journey
7. Hepatitis B Virus Epidemiology and Patient Population
8. Hepatitis B Virus Treatment Algorithm, Current Treatment, and Medical Practices
9. Hepatitis B Virus Unmet Needs
10. Key Endpoints of Hepatitis B Virus Treatment
11. Hepatitis B Virus Marketed Products
12. Hepatitis B Virus Emerging Therapies
13. Hepatitis B Virus Seven Major Market Analysis
14. Attribute Analysis
15. Hepatitis B Virus Market Outlook (7 major markets)
16. Hepatitis B Virus Access and Reimbursement Overview
17. KOL Views on the Hepatitis B Virus Market.
18. Hepatitis B Virus Market Drivers
19. Hepatitis B Virus Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Hepatitis B Virus (HBV) Infection Epidemiology Forecast to 2030
DelveInsight’s Hepatitis B Virus (HBV) Infection Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hepatitis B Virus (HBV) Infection in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Hepatitis B Virus (HBV) Infection Pipeline Insights, 2020
Hepatitis B Virus (HBV) Infection Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hepatitis B Virus (HBV) Infection market.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States